RT Journal Article
SR Electronic
T1 Viral and Host Mediators of Non-Suppressible HIV-1 Viremia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.30.23287124
DO 10.1101/2023.03.30.23287124
A1 Mohammadi, Abbas
A1 Etemad, Behzad
A1 Zhang, Xin
A1 Li, Yijia
A1 Bedwell, Gregory J.
A1 Sharaf, Radwa
A1 Kittilson, Autumn
A1 Melberg, Meghan
A1 Wong, Colline
A1 Fajnzylber, Jesse
A1 Worrall, Daniel P.
A1 Rosenthal, Alex
A1 Jordan, Hannah
A1 Jilg, Nikolaus
A1 Kaseke, Clarety
A1 Giguel, Francoise
A1 Lian, Xiaodong
A1 Deo, Rinki
A1 Gillespie, Elisabeth
A1 Chishti, Rida
A1 Abrha, Sara
A1 Adams, Taylor
A1 Siagian, Abigail
A1 Anderson, Peter L.
A1 Deeks, Steven G.
A1 Lederman, Michael M.
A1 Yawetz, Sigal
A1 Kuritzkes, Daniel R.
A1 Lichterfeld, Mathias D.
A1 Tsibris, Athe
A1 Carrington, Mary
A1 Brumme, Zabrina L.
A1 Castillo-Mancilla, Jose R.
A1 Engelman, Alan N.
A1 Gaiha, Gaurav D.
A1 Li, Jonathan Z.
YR 2023
UL http://medrxiv.org/content/early/2023/03/31/2023.03.30.23287124.abstract
AB Non-suppressible HIV-1 viremia (NSV) can occur in persons with HIV despite adherence to combination antiretroviral therapy (ART) and in the absence of significant drug resistance. Here, we show that plasma NSV sequences are comprised primarily of large clones without evidence of viral evolution over time. We defined proviruses that contribute to plasma viremia as “producer”, and those that did not as “non-producer”. Compared to ART-suppressed individuals, NSV participants had a significantly larger producer reservoir. Producer proviruses were enriched in chromosome 19 and in proximity to the activating H3K36me3 epigenetic mark. CD4+ cells from NSV participants demonstrated upregulation of anti-apoptotic genes and downregulation of pro-apoptotic and type I/II interferon-related pathways. Furthermore, NSV participants showed no elevation in HIV-specific CD8+ cell responses and producer proviruses were enriched for HLA escape mutations. We identified critical host and viral mediators of NSV that represent potential targets to disrupt HIV persistence and promote viral silencing.Competing Interest StatementJRCM has received funding from Gilead Sciences for investigator initiated research paid to his institution. PLA has received past consulting fees from Gilead, ViiV and Merck and research funding from Gilead paid to institution, unrelated to this work. JZL has consulted for Abbvie and received grant funding from Merck.Funding StatementThis work was supported in part by the Harvard University Center for AIDS Research (AI060354), NIH grants AI169768 (JZL), AI068634, AI068636 and AI106701. This project has been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. 75N91019D00024. R37AI039394 (ANE), U54AI170791 (ANE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Mass General Brigham gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors